Please login to the form below

Not currently logged in
Email:
Password:

Pfizer’s Elizabeth Barrett joins Novartis as its oncology head

She succeeds Bruno Strigini who retires

Elizabeth BarrettNovartis has appointed Elizabeth Barrett to head up its oncology franchise based at the group’s headquarters in Switzerland.

Barrett, who succeeds Bruno Strigini, has held numerous leadership positions in the pharmaceutical industry as well as in the commercial sector.

She most recently served Pfizer, leading its oncology business but has held several roles with the pharma giant including president, Europe, president North America, speciality care and US president of oncology.

She said: “I feel honoured to join Novartis. It is key to me to contribute to transformative advancements in oncology, and to serve in a highly impactful leadership role to this end.”

Prior to her time with Pfizer, Barrett held roles with Cephalon and Johnson & Johnson.

Vas Narasimhan, chief executive officer at Novartis, said: “Liz is a highly accomplished and recognised oncology and people leader with an impressive record of building successful business organisations in the US.

“She has been instrumental in creating new commercial models, driving innovation in close partnership with research and development and leveraging business development opportunities.

“Her long-time commercial pharma industry experience, marketing skills and perspectives make Liz a great fit to further develop our oncology business.”

12th January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics